Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study

Patients with advanced non-small cell lung cancer who exhibit immune-acquired resistance may still derive clinical benefit from rechallenging with immune checkpoint inhibitors, particularly in those with a favorable ECOG performance status. Further prospective clinical trials and molecular investigations are necessary to validate these findings and better define the patient subgroups most likely to benefit from this therapeutic approach.